Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease?

Research output: Contribution to journalArticle

Abstract

Levodopa-induced dyskinesias (LIDs) represent one major motor disability of Parkinson's disease (PD) therapy. Thus, research effort is still devoted to finding agents that may improve parkinsonism and concomitantly reduce or avoid dyskinesia. Rodent and nonhuman primate models provide useful tools to study the molecular and neuronal bases of LIDs. Among the various strategies investigated recently, the use of drugs targeting metabotropic glutamate receptors has received large attention. In particular, use of antagonists of the subtype 5 of metabotropic glutamate receptors revealed promising preclinical and clinical results.

Original languageEnglish
Pages (from-to)715-719
Number of pages5
JournalMovement Disorders
Volume29
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Metabotropic Glutamate Receptors
Dyskinesias
Levodopa
Parkinson Disease
Metabotropic Glutamate 5 Receptor
Parkinsonian Disorders
Drug Delivery Systems
Primates
Rodentia
Research
Therapeutics

Keywords

  • Dyskinesia
  • Experimental animal models
  • Levodopa therapy
  • MGluR5
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

@article{4de0f4e0f5c542f9a4d32152e392ae10,
title = "Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease?",
abstract = "Levodopa-induced dyskinesias (LIDs) represent one major motor disability of Parkinson's disease (PD) therapy. Thus, research effort is still devoted to finding agents that may improve parkinsonism and concomitantly reduce or avoid dyskinesia. Rodent and nonhuman primate models provide useful tools to study the molecular and neuronal bases of LIDs. Among the various strategies investigated recently, the use of drugs targeting metabotropic glutamate receptors has received large attention. In particular, use of antagonists of the subtype 5 of metabotropic glutamate receptors revealed promising preclinical and clinical results.",
keywords = "Dyskinesia, Experimental animal models, Levodopa therapy, MGluR5, Parkinson's disease",
author = "Barbara Picconi and Paolo Calabresi",
year = "2014",
doi = "10.1002/mds.25851",
language = "English",
volume = "29",
pages = "715--719",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease?

AU - Picconi, Barbara

AU - Calabresi, Paolo

PY - 2014

Y1 - 2014

N2 - Levodopa-induced dyskinesias (LIDs) represent one major motor disability of Parkinson's disease (PD) therapy. Thus, research effort is still devoted to finding agents that may improve parkinsonism and concomitantly reduce or avoid dyskinesia. Rodent and nonhuman primate models provide useful tools to study the molecular and neuronal bases of LIDs. Among the various strategies investigated recently, the use of drugs targeting metabotropic glutamate receptors has received large attention. In particular, use of antagonists of the subtype 5 of metabotropic glutamate receptors revealed promising preclinical and clinical results.

AB - Levodopa-induced dyskinesias (LIDs) represent one major motor disability of Parkinson's disease (PD) therapy. Thus, research effort is still devoted to finding agents that may improve parkinsonism and concomitantly reduce or avoid dyskinesia. Rodent and nonhuman primate models provide useful tools to study the molecular and neuronal bases of LIDs. Among the various strategies investigated recently, the use of drugs targeting metabotropic glutamate receptors has received large attention. In particular, use of antagonists of the subtype 5 of metabotropic glutamate receptors revealed promising preclinical and clinical results.

KW - Dyskinesia

KW - Experimental animal models

KW - Levodopa therapy

KW - MGluR5

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=84899939104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899939104&partnerID=8YFLogxK

U2 - 10.1002/mds.25851

DO - 10.1002/mds.25851

M3 - Article

C2 - 24591264

AN - SCOPUS:84899939104

VL - 29

SP - 715

EP - 719

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 6

ER -